Correction to: Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation
Percy AJ, Byrns S, Chambers AG, Borchers CH. Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation. Expert Rev. Proteomics 2013;10(6):567-78.
Following publication of this article, a printing error has been identified in . was printed twice instead of printing . The corrected is shown below:
Figure 4. A strategy for peptide interference-screening in control and patient plasma samples (continued on page 573). (A) In the control samples, three transitions per peptide are monitored in buffer and plasma (n = 2 for each sample type) for determination of average relative ratios of the Q1/Q3 MRM ion pairs (for the SIS peptide in buffer, the SIS peptide in plasma, and the NAT peptide in plasma) and variability (see table inset), as well as the assessment of peak shape, symmetry and retention time. (B) In the patient samples, interferences can be detected through peptide relative response correlation plots for each protein. For the samples that deviate from linearity (see sample marked with arrow), peptide XICs are inspected to determine the interference-containing peptide.
